333 W. SANTA CLARA STREET, SUITE 900, SAN JOSE, CA
Market cap: $35.6M (2/10/2026)
Price: $0.97
Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
RenovoRx Enters $3.7M Capital on Demand Sales Agreement with JonesTrading
Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update
Financial Results, Other Events
Shareholder votes
Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Q3
Q1
Notice of Late Filing for Annual Report
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-8 POS